These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20803321)

  • 1. Drug treatment as HIV prevention: expanding treatment options.
    Metzger DS; Zhang Y
    Curr HIV/AIDS Rep; 2010 Nov; 7(4):220-5. PubMed ID: 20803321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug treatment as HIV prevention: a research update.
    Metzger DS; Woody GE; O'Brien CP
    J Acquir Immune Defic Syndr; 2010 Dec; 55 Suppl 1(Suppl 1):S32-6. PubMed ID: 21045597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.
    Alistar SS; Owens DK; Brandeau ML
    PLoS Med; 2011 Mar; 8(3):e1000423. PubMed ID: 21390264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interest in use of mHealth technology in HIV prevention and associated factors among high-risk drug users enrolled in methadone maintenance program.
    Shrestha R; Karki P; Copenhaver M
    AIDS Care; 2017 Sep; 29(9):1144-1148. PubMed ID: 28478706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.
    Metzger DS; Donnell D; Celentano DD; Jackson JB; Shao Y; Aramrattana A; Wei L; Fu L; Ma J; Lucas GM; Chawarski M; Ruan Y; Richardson P; Shin K; Chen RY; Sugarman J; Dye BJ; Rose SM; Beauchamp G; Burns DN;
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):554-61. PubMed ID: 25564105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV seroconversion and risk factors among drug users receiving methadone maintenance treatment in China: A qualitative study.
    Wang C; Shi CX; Zhang B; Chen H; Wang H; Zhang N; Rou K; Cao X; Luo W; Wu Z
    Drug Alcohol Depend; 2016 Oct; 167():169-74. PubMed ID: 27567967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral suppression among HIV-infected methadone-maintained patients: The role of ongoing injection drug use and adherence to antiretroviral therapy (ART).
    Shrestha R; Copenhaver MM
    Addict Behav; 2018 Oct; 85():88-93. PubMed ID: 29879611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran.
    Farnia M; Ebrahimi B; Shams A; Zamani S
    Int J Drug Policy; 2010 Sep; 21(5):422-4. PubMed ID: 20413287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid treatment in Ukraine risks losing momentum.
    Bull World Health Organ; 2013 Feb; 91(2):87-8. PubMed ID: 23554519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigating the risk of HIV infection with opioid substitution treatment.
    Gowing LR; Hickman M; Degenhardt L
    Bull World Health Organ; 2013 Feb; 91(2):148-9. PubMed ID: 23554530
    [No Abstract]   [Full Text] [Related]  

  • 11. Methadone maintenance as HIV risk reduction with street-recruited injecting drug users.
    Kwiatkowski CF; Booth RE
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):483-9. PubMed ID: 11391170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission.
    Bachireddy C; Weisberg DF; Altice FL
    Addiction; 2015 Dec; 110(12):1869-71. PubMed ID: 26464200
    [No Abstract]   [Full Text] [Related]  

  • 13. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications.
    Bruce RD; Dvoryak S; Sylla L; Altice FL
    Int J Drug Policy; 2007 Aug; 18(4):326-8. PubMed ID: 17689382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of methadone maintenance therapy as HIV prevention in an Indonesian high-prevalence setting: a mathematical modeling study.
    Wammes JJ; Siregar AY; Hidayat T; Raya RP; van Crevel R; van der Ven AJ; Baltussen R
    Int J Drug Policy; 2012 Sep; 23(5):358-64. PubMed ID: 22884538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: results from the MANIF 2000 cohort study.
    Carrieri MP; Roux P; Cohen J; Ravaux I; Dellamonica P; Protopopescu C; Spire B; Rosenblum A
    Addiction; 2010 Dec; 105(12):2160-8. PubMed ID: 20840169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychoeducational group approach: HIV risk reduction in drug users.
    Sorensen JL; London J; Heitzmann C; Gibson DR; Morales ES; Dumontet R; Acree M
    AIDS Educ Prev; 1994 Apr; 6(2):95-112. PubMed ID: 8018443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-efficacy and HIV risk behaviors among heroin users in Taiwan.
    Ko NY; Wang PW; Wu HC; Yen CN; Hsu ST; Yeh YC; Chung KS; Yen CF
    J Stud Alcohol Drugs; 2012 May; 73(3):469-76. PubMed ID: 22456252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study.
    Ayres R; Ingram J; Rees A; Neale J; Beattie A; Telfer M
    Subst Abuse Treat Prev Policy; 2014 Nov; 9():44. PubMed ID: 25407020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.